FY2025 (Fiscal Year Ending January 2026) Financial Supplementary Presentation Materials

Overview of Performance

Consolidated net sales for FY2025 reached JPY 241,236 million, representing a 1.7% increase year-over-year; however, operating income declined by 13.1% to JPY 4,163 million. Notably, net income attributable to owners of the parent plummeted from a profit of JPY 3,432 million in the previous year to a loss of JPY 31,330 million, significantly impacted by impairment losses amounting to JPY 29,826 million. Segment-wise, the domestic beverage business recorded net sales of JPY 142,651 million, a 3.3% decrease from the prior year, along with operating losses. Conversely, the overseas beverage business saw net sales rise 16.1% to JPY 65,341 million, also posting higher operating income. The rare disease pharmaceuticals business experienced substantial sales growth; however, losses continue. Capital expenditures increased to JPY 16,414 million, reflecting ongoing investments aimed at future growth.

Outlook and Challenges

The earnings forecast for FY2026 anticipates net sales of JPY 246,800 million, a 2.3% increase YoY, with a significant rise in operating income projected at JPY 10,500 million. The domestic beverage business is expected to return to profitability, while profit outlooks for the pharmaceutical-related and rare disease pharmaceuticals businesses are forecasted to decline. Continued impacts from hyperinflation accounting adjustments at the Turkish subsidiary have been factored in. Key challenges include improving the financial position and strengthening the earnings base.